Alan L Schneider1, Terry L Schneider, Harry Stark. 1. Gateways Hospital and Mental Health Center, University of California-Los Angeles School of Medicine, Los Angeles, CA 90026, USA. alsmd@roadrunner.com
Abstract
BACKGROUND: In the absence of effective treatments for the negative symptom complex of schizophrenia, we explored the effect of 4 consecutive weeks of repetitive transcranial magnetic stimulation (rTMS) exposure (20 sessions) as an add-on treatment to atypical antipsychotics. METHODS: Three groups of 17 schizophrenic subjects each were exposed to 20 treatments of either placebo, 1 Hz (100 pulses per day=2000 total) or 10 Hz (1000 pulses per day=20,000 total) rTMS at 110% motor threshold over the left dorsolateral prefrontal cortex, while being maintained on their atypical antipsychotic. Subjects were evaluated at baseline, weeks 2 and 4, and at 4-week follow-up after the last treatment. RESULTS: The primary outcome measure (change in Scale for Assessment of Negative Symptoms score) showed a statistically significant drop at weeks 2, 4, and 8 for the high frequency (10 Hz) group, but not the 1 Hz or placebo groups. Secondary outcome measures of the Wisconsin Card Sorting Test and SF-36 did not demonstrate any significant change. CONCLUSIONS:rTMS may serve as a relatively noninvasive treatment of the negative and neurocognitive deficits associated with schizophrenia.
RCT Entities:
BACKGROUND: In the absence of effective treatments for the negative symptom complex of schizophrenia, we explored the effect of 4 consecutive weeks of repetitive transcranial magnetic stimulation (rTMS) exposure (20 sessions) as an add-on treatment to atypical antipsychotics. METHODS: Three groups of 17 schizophrenic subjects each were exposed to 20 treatments of either placebo, 1 Hz (100 pulses per day=2000 total) or 10 Hz (1000 pulses per day=20,000 total) rTMS at 110% motor threshold over the left dorsolateral prefrontal cortex, while being maintained on their atypical antipsychotic. Subjects were evaluated at baseline, weeks 2 and 4, and at 4-week follow-up after the last treatment. RESULTS: The primary outcome measure (change in Scale for Assessment of Negative Symptoms score) showed a statistically significant drop at weeks 2, 4, and 8 for the high frequency (10 Hz) group, but not the 1 Hz or placebo groups. Secondary outcome measures of the Wisconsin Card Sorting Test and SF-36 did not demonstrate any significant change. CONCLUSIONS: rTMS may serve as a relatively noninvasive treatment of the negative and neurocognitive deficits associated with schizophrenia.
Authors: Mei Hong Xiu; Heng Yong Guan; Jian Min Zhao; Ke Qiang Wang; Yan Fen Pan; Xiu Ru Su; Yu Hong Wang; Jin Ming Guo; Long Jiang; Hong Yu Liu; Shi Guang Sun; Hao Ran Wu; Han Song Geng; Xiao Wen Liu; Hui Jing Yu; Bao Chun Wei; Xi Po Li; Tammy Trinh; Shu Ping Tan; Xiang Yang Zhang Journal: Schizophr Bull Date: 2020-03-17 Impact factor: 9.306
Authors: Stephen J Brandt; Halimah Y Oral; Carla Arellano-Bravo; Martin H Plawecki; Tom A Hummer; Michael M Francis Journal: Neurotherapeutics Date: 2021-04-12 Impact factor: 7.620